GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Return-on-Tangible-Asset

RemeGen Co (HKSE:09995) Return-on-Tangible-Asset : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. RemeGen Co's annualized Net Income for the quarter that ended in Dec. 2023 was HK$0.0 Mil. RemeGen Co's average total tangible assets for the quarter that ended in Dec. 2023 was HK$5,889.4 Mil. Therefore, RemeGen Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for RemeGen Co's Return-on-Tangible-Asset or its related term are showing as below:

HKSE:09995' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -70.83   Med: -27.98   Max: 6.86
Current: -11.59

During the past 6 years, RemeGen Co's highest Return-on-Tangible-Asset was 6.86%. The lowest was -70.83%. And the median was -27.98%.

HKSE:09995's Return-on-Tangible-Asset is ranked better than
73.5% of 1551 companies
in the Biotechnology industry
Industry Median: -39.81 vs HKSE:09995: -11.59

RemeGen Co Return-on-Tangible-Asset Historical Data

The historical data trend for RemeGen Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Return-on-Tangible-Asset Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -70.83 -29.62 6.86 -19.08 -26.34

RemeGen Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.83 - -22.10 - -25.74

Competitive Comparison of RemeGen Co's Return-on-Tangible-Asset

For the Biotechnology subindustry, RemeGen Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Return-on-Tangible-Asset falls into.



RemeGen Co Return-on-Tangible-Asset Calculation

RemeGen Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-1652.95/( (6661.571+5889.41)/ 2 )
=-1652.95/6275.4905
=-26.34 %

RemeGen Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=0/( (0+5889.41)/ 1 )
=0/5889.41
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


RemeGen Co  (HKSE:09995) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


RemeGen Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co (HKSE:09995) Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines